The role of thalidomide in myeloma patients eligible for high-dose therapy

被引：0
|
作者：
Cavo, M. [1 ]
机构：
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [31] Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
    R Fenk
    B Hoyer
    U Steidl
    M Kondakci
    T Graef
    R Heuk
    L Ruf
    C Strupp
    F Neumann
    U-P Rohr
    B Hildebrandt
    R Haas
    G Kobbe
    Leukemia, 2005, 19 : 156 - 159
  • [32] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [33] A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
    Lokhorst, Henk M.
    van der Holt, Bronno
    Zweegman, Sonja
    Vellenga, Edo
    Croockewit, Sandra
    van Oers, Marinus H.
    Borne, Peter von dem
    Wijermans, Pierre
    Schaafsma, Ron
    de Weerdt, Okke
    Wittebol, Shulamiet
    Delforge, Michel
    Berenschot, Henriette
    Bos, Gerard M.
    Jie, Kon-Siong G.
    Sinnige, Harm
    van Marwijk-Kooy, Marinus
    Joosten, Peter
    Minnema, Monique C.
    van Ammerlaan, Rianne
    Sonneveld, Pieter
    BLOOD, 2010, 115 (06) : 1113 - 1120
  • [34] Outpatient high-dose melphalan in multiple myeloma patients
    Kassar, Mohamad
    Medoff, Erin
    Seropian, Stuart
    Cooper, Dennis L.
    TRANSFUSION, 2007, 47 (01) : 115 - 119
  • [35] Daily low dose thalidomide plus monthly high-dose dexamethasone as consolidation/maintenance treatment in elderly multiple myeloma (MM) patients
    Vigna, E.
    Mazzone, C.
    Gentile, M.
    Lucia, E.
    Iorio, C.
    Morelli, R.
    Bisconte, M. G.
    Gentile, C.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 143 - 143
  • [36] Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy
    Corso, Alessandro
    Barbarano, Luciana
    Mangiacavalli, Silvia
    Montalbetti, Luigi
    Brasca, Paola
    Zappasodi, Patrizia
    Carella, Angelo
    Spriano, Mauro
    Alessandrino, Emilio Paolo
    Cairoli, Roberto
    Petro, Daniela
    Varettoni, Marzia
    Bernasconi, Paolo
    Lazzarino, Mario
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 1051A - 1052A
  • [37] Risk driven decision for high-dose therapy in multiple myeloma - No
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 242 - 242
  • [38] THALIDOMIDE-DEXAMETHASONE (THALDEX) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS RELAPSING AFTER HIGH DOSE THERAPY AND AUTOPBSCT
    Charlinski, G.
    Barwicka, M.
    Wiater, E.
    Dwilewicz-Trojaczek, J.
    Wiktor-Jedrzejczak, W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 262 - 263
  • [39] Thalidomide therapy and polyneuropathy in myeloma patients
    Laaksonen, S
    Remes, K
    Koskela, K
    Voipio-Pulkki, LM
    Falck, B
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2005, 10 : 48 - 49
  • [40] AN INCREMENTAL RESPONSE TO HIGH-DOSE THERAPY IN MULTIPLE-MYELOMA
    HAWKINS, T
    HORVATH, N
    RAWLING, C
    BAYLY, J
    ANDARY, V
    DYSON, P
    HO, J
    DART, G
    JUTTNER, C
    TO, L
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 759 - 759
12345